Mr. Arun Kumar S. T.
MSc (Area): Biochemistry
Arun Kumar S. T. completed his Masters in Biochemistry from Bangalore University (2008). He started his career as a JRF at St. John’s Medical College Hospital under ICMR project titled “Molecular Characterization of Hemoglobinopathies” under the guidance of Prof Cecil Ross, also simultaneously he has been a part of the team working on cloning the CML fusion gene into HeLa cell lines to study the characteristics of BCR-ABL fusion proteins at NCBS. Later he went on to work with industry. His expertise is on molecular diagnostics of infectious diseases and Leukemia (DNA/RNA based). During his previous tenures, he was responsible for standardizing Real Time Molecular diagnostic kits (Taqman based) for various Infectious diseases, Oncology (Relative quants), Nucleic acid purification kits (Magnetic bead based & spin column), LINE probe hybridization assays for MTB (MDR/XDR) & LAMP. He is also an LSSSDC certified trainer for QA/QC Biologists, Product development and Business Development.
- Assistant Professor (Apr 2018 – May 2019) – Dept. of Biotechnology, BISEP, The Oxford College of Science, Bangalore
- Associate Manager (Dec 2014 – Mar 2018) – Product Management, Sasvat Omnicare Pvt. Ltd. (Green Apple)., Bangalore
- R&D – Applications & Operations (Dec 2012 – Dec 2014) – Serene Cell Science & Technologies, Bangalore
- Application Specialist (Dec 2010 –Dec 2011) – Molecular Biology and Drug discovery, Biotron Healthcare (I) Pvt. Ltd., Bangalore
- Research Associate (Jul 2008 – Nov 2010) – St John’s Medical College Hospital, Bangalore
- Research Assistant (Jan 2008 – Apr 2008) (Part-time) – R.V. Chemistry Research Centre, Bangalore
Immunology, Global cell signaling, Molecular Diagnostics, Discovery Biology – Proteomics and Metabolomics of Infectious diseases
Current work in CSBMM is focused on development of spectral libraries for quantitative DIA Mass Spectrometry based methods for early diagnosis and identification of various Infectious diseases from serum/urine. Translation of discovered diagnostic biomarkers into non-invasive rapid point of care (POC) diagnostic test kit panels.